Clinical trials: Circulatory Failure (Shock)
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Myocardial Infarction, Cardiogenic Shock
Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction.
- Trial name
- NCT06955936
- Testing
- Efferon CT
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Efferon JSC
Shock, Hemodynamic Instability
Hemodynamic Instability Index: The Impact to Care With a New Predictive Indicator
Philips has developed a new algorithm, called Hemodynamic Instability Rules Based Advisor (HIRBA 2.0) system, for the prediction of hemodynamic instability in critically ill patients, who were not previously known to be at risk.
- Trial name
- HII (NCT02185521)
- Testing
- patient assessment
- Where
- 2 sites in United States
- Volunteers
- 127 people
- Sponsor
- Philips Healthcare
Cardiac Arrest, Heart Arrest
ICD Shock Detection by a Wearable
Trial to assess the ability of a wearable to detect defibrillation from an implantable ICD
- Conditions
- Cardiac Arrest, Heart Arrest, Cardiopulmonary Arrest
- Trial name
- LOISICD (NCT04565652)
- Testing
- Device Wearers
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Lois Medical LTD
Lymphoma, Follicular, Lymphoma, Small Lymphocytic
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Primary Objectives: To document the efficacy of treatment with autologous lymphoma-derived HSPPC-96 of selected patients with indolent lymphoma.
- Trial name
- NCT00081809
- Testing
- autologous human tumor-derived HSPPC-96
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Agenus Inc.
Cardiovascular Disease
Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming
The purpose of this clinical trial is to determine whether periodic therapy programming reports illustrating physician usage of shock reduction programming can increase utilization of recommended programming guidelines for…
- Trial name
- NCT00856349
- Testing
- Therapy Programming Report (TPR)
- Where
- 104 sites in United States, Argentina and 10 more
- Volunteers
- 4,384 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Shock
Enhanced Surveillance of RV Lead Integrity Alert (RVLIA)
The purpose is to prospectively monitor the performance of the RV Lead Integrity Alert (LIA) upon commercial release.
- Trial name
- RVLIA (NCT00824915)
- Volunteers
- 1,779 people, healthy volunteers welcome
- Sponsor
- Medtronic
Septic Shock
Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock
The purpose of this trial is to investigate the potential of FE 202158 as a treatment which can stabilize blood pressure for treatment of patients in early septic shock.
- Trial name
- NCT01612676
- Testing
- FE 202158
- Where
- 4 sites in Belgium, Denmark
- Volunteers
- 31 people
- Sponsor
- Ferring Pharmaceuticals
Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
This was a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia…
- Trial name
- CAN-COVID (NCT04362813)
- Testing
- Canakinumab
- Where
- 39 sites in United States, France and 4 more
- Volunteers
- 454 people
- Sponsor
- Novartis Pharmaceuticals
Covid19, Cytokine Release Syndrome
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
The purpose of this study is to assess the safety and efficacy of orally administered NLRP3 inhibitor, dapansutrile, for the treatment of moderate COVID-19 symptoms and early cytokine release syndrome (CRS) in patients with…
- Trial name
- NCT04540120
- Testing
- dapansutrile capsules
- Where
- 10 sites in United States, Switzerland
- Volunteers
- 49 people
- Sponsor
- Olatec Therapeutics, Inc.
Severe Sepsis
A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
A study to evaluate the safety, tolerability and pharmacokinetics of Nivolumab in participants with severe sepsis or septic shock.
- Trial name
- NCT02960854
- Testing
- Nivolumab
- Where
- 16 sites in United States
- Volunteers
- 38 people
- Sponsor
- Bristol-Myers Squibb
Plantar Fasciitis
Study of Effectiveness and Safety of Extracorporeal Shock Wave Therapy (ESWT) for Treatment of Painful Heel Syndrome
The purpose of this study is to determine if the Storz Duolith SD1 is more effective than placebo for treatment of heel pain syndrome for patients who have failed conservative treatment with other therapies.
- Trial name
- ESWT (NCT00720694)
- Testing
- Duolith SD1
- Where
- 6 sites in United States
- Volunteers
- 250 people
- Sponsor
- Storz Medical AG
Immunity, Vaccine Reaction
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
The immune system response needs to be forceful but also balanced for a rapid recovery from infection which avoids harmful overreactions.
- Conditions
- Immunity, Vaccine Reaction, Influenza, Covid19
- Trial name
- NCT04798677
- Testing
- ABBC1 Immunoessential
- Where
- Spain
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AB Biotek
Sleep Apnea, Obstructive
The PREDICTOR Study: Assessing Diagnostic Predictors of Airway Collapse in Patients With Obstructive Sleep Apnea
This study is an exploratory, multicenter study of up to 300 subjects diagnosed with obstructive sleep apnea who are being evaluated for airway surgery.
- Trial name
- PREDICTOR (NCT05428839)
- Testing
- Pharyngeal width measurement
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- Inspire Medical Systems, Inc.
COVID-19
101-PGC-005 for the Treatment of COVID-19
This is a prospective, randomized, comparative, multi-centric, adaptive design clinical study to evaluate efficacy, safety, and tolerability of 101-PGC-005 ('005) when used alongside standard of care (SOC) for the treatment of…
- Trial name
- NCT05656521
- Testing
- 101-PGC-005, Dexamethasone
- Where
- 5 sites in India
- Volunteers
- 62 people
- Sponsor
- 101 Therapeutics
Heart Failure, Cardiogenic Shock
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
- Conditions
- Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
- Trial name
- INTeGRATE (NCT06965504)
- Testing
- Impella 5.5 SmartAssist
- Where
- 17 sites in United States
- Volunteers
- 250 people
- Sponsor
- Abiomed Inc.
Coronavirus Disease 2019 (COVID-19) Pneumonia
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and improve ventilator-free survival in…
- Trial name
- NCT04351152
- Testing
- Lenzilumab, Standard of Care
- Where
- 29 sites in United States, Brazil
- Volunteers
- 520 people
- Sponsor
- Humanigen, Inc.
COVID-19, COVID-19 Pandemic
PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19
A galectin antagonist prevents viral entry of Sars-CoV-2 virus by blocking the specific terminal on the surface receptors that enables the virus to enter human cells.
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS-CoV2 Infection
- Trial name
- PROTECT (NCT05096052)
- Testing
- Galactomannan
- Volunteers
- 408 people
- Sponsor
- Bioxytran Inc.
Sepsis, Septic Shock
Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis
The purpose of this prospective, non-interventional, multi-centre clinical study is to assess the clinical validity of the Heparin Binding Protein (HBP) assay for indicating the presence, or outcome, of severe sepsis (including…
- Conditions
- Sepsis, Septic Shock, Sepsis With Acute Organ Dysfunction
- Trial name
- NCT03113721
- Where
- 5 sites in United States
- Volunteers
- 571 people
- Sponsor
- Axis Shield Diagnostics Ltd
Erectile Dysfunction
DualStim Therapy With or Without Umbilical Cord Derived Wharton's Jelly for Erectile Dysfunction
The purpose of this study is to determine the immediate and short-term efficacy of the methodological application of DualStim Therapy - Focused Extracorporeal Shock Wave Therapy (fESWT) and Radial Extracorporeal Shock Wave…
- Trial name
- NCT04424394
- Testing
- DualStim Therapy, Umbilical cord-derived Wharton's Jelly, Saline
- Volunteers
- 60 people
- Sponsor
- BioIntegrate